The TSM Advantage

The TSM Advantage 2018-03-15T11:17:22+00:00

The TSM Difference

The TSM profile will:

  • Identify the genomic context of the mutations
  • Identify the source of the mutations
  • Generate an Innate Immune Fitness Profile by combining genomic context and source metrics

The most common genetic tests are based on SNPs. In oncology a single SNP or multiple SNPs can only ever provide an indication of cancer pre-disposition. The identification of mutations in oncogenes is also used in some diagnostic tools. Epigenetic tests for methylated genes, and tests for cancer-associated miRNAs are not accurate, and they are most often used for patients with a late stage diagnosis. Recently there has been a lot of focus on the diagnostic use of tests to detect ctDNA. However, Bettegowda et al (2014)[1] showed that ctDNA was detected in only 75% of patients with metastatic disease. By then it is often too late, and little or no clinically relevant information can be interpreted from the results. The provision of ‘personal profiles’ has also recently been introduced to the genetic test market. This involves the bundling of several of the above types of genetic tests together. Some are used for prognostication and for identifying the most appropriate therapy regime. However, the sensitivity and specificity of tests so far are low. A comprehensive overview demonstrating the diversity of applications using these genomic test approaches is provided in a recent Kelly Scientific Publications Report (2016).[1]

The GMDx Co. profile identifies the source of mutation(s) and provides an indication of the SHM-like profile that is unique for each individual with additional data to guide the selection of treatment(s). TSM testing can be applied in screening an individual and also applied in oncology at all stages. The GMDX Co. TSM profile is unique in the ability to identify the source of the mutations giving rise to disease.

The TSM profile is the only one identifying the source of mutations that have remained uncorrected and therefore need to be identified for personalised and targeted therapy. Current genetic tests are limited in their ability to provide insight into the associations between immune-like functions and diseases affecting somatic tissues.
The advantages of the TSM profile are:

  • Identifies the SOURCE of endogenous and exogenous mutagens giving rise to disease;
  • Identifies the genomic context of the mutations; and,
  • Provides clinically relevant insights into links between a patient’s IMMUNE FUNCTION and disease progression

[1] Kelly Scientific Publications (2016). Personalised Medicine, Targeted Therapeutics & Companion Diagnostic Market: A Strategic Analysis of Industry Trends, Technologies, Participants & Environment. Available at: